XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.2
DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended 21 Months Ended 62 Months Ended
Apr. 24, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Apr. 23, 2024
Apr. 23, 2024
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Loss on disposal of discontinued operations     $ (1,799,000) $ 0 $ (1,799,000)      
Revenue from collaborative agreement   $ 0 302,000 0 1,275,000      
Accounts receivable   1,859,000   1,859,000       $ 1,694,000
Total revenues | Rezafungin                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Liabilities related to discontinued operations   0   0       0
Assets related to discontinued operations   0   0       0
Cash provided by (used in) operating activities, discontinued operations         17,600,000      
Cash provided by (used in) financing activities, discontinued operations         0      
Cash provided by (used in) investing activities, discontinued operations         0      
Total revenues     21,762,000   29,252,000      
Loss on disposal of discontinued operations     (1,799,000)   (1,799,000)      
Total revenues | Rezafungin | Related Party | Collaborative Arrangement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Revenue, remaining performance obligation, amount   0   0        
Accounts receivable   0   0       $ 0
Napp Pharmaceutical Group Limited | Total revenues | Rezafungin | Related Party | Collaborative Arrangement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Collaborative agreement, maximum cost share, forgiveness amount $ 11,100,000              
Collaborative arrangement, carry over services agreement term (in days) 45 days              
Collaborative arrangement, other services agreement term (in days) 75 days              
Collaborative arrangement, transaction, value $ 21,200,000              
Contract liabilities, forgiveness amount 25,300,000              
Transition services 600,000              
Payments related to collaborative agreement 2,100,000              
Accounts receivable, forgiveness amount 2,600,000              
Total revenues     100,000          
Loss on disposal of discontinued operations $ 300,000              
Collaborative arrangement, transitions services term (in days) 76 days              
Revenue, remaining performance obligation, amount   0   0        
Accounts receivable   $ 1,900,000   $ 1,900,000        
Napp Pharmaceutical Group Limited | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Rezafungin Assets, including Sale of Intellectual Property and Inventory                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Total revenues $ 20,800,000              
Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Payments related to collaborative agreement           $ 30,000,000    
Revenue from collaborative agreement     189,000   582,000      
Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Milestone Achievement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Revenue from collaborative agreement           $ 20,000,000    
Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Payments related to collaborative agreement             $ 30,000,000  
Collaborative agreement, maximum cost share             31,200,000  
Revenue from collaborative agreement     $ 21,573,000   $ 28,670,000      
Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Milestone Achievement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Revenue from collaborative agreement             $ 27,900,000